Pulmonary arterial hypertension
Conditions
Interventions
We will look at the effects of vasodilators such as endothelin antagonists, phosphodiesterase-5 inhibitors, or their combination on pulmonary hypertension and myocardial oxidative metabolism. PH pati
Sponsors
Hokkaido University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with symptomatic pulmonary hypertension (WHO functional class II to IV) despite treatment with anticoagulant drugs, vasodilators, diuretic or supplemental oxygen. Pulmonary artery hypertension will be either primary, chronic peripheral pulmonary artery thrombosis, or associated with connective-tissue disease. Age less than 20 when their guardian agrees with the entry.
Exclusion criteria
Exclusion criteria: Patients with coronary artery disease life expectancy less than 1 year due to other co-morbidity paced rhythm Prior diagnostic sleep related disorder. inability to obtain informed consent pregnant or breast-feeding claustrophobia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| WHO functional class, 6-minute walk. Positron emission tomography: 11C acetate PET for evaluating myocardial oxidative metabolism and efficiency. 15O labeled water for evaluating myocardial blood flow and coronary resistance. Right heart catheterization for evaluating pulmonary arterial pressure and pulmonary arterial resistance. Echocardioghraphy, cardiac magnetic resonance imaging, ECG, and biomarkers from blood samples. | — |
Countries
Japan
Contacts
Public ContactKeiichiro Yoshinaga, M.D., Ph.D, F.A.C.C..
Hokkaido University Graduate School of Medicine Department of Photobiology
Outcome results
None listed